-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Initiated by Baitai Biopharmaceutical Co.
, Ltd.
, and jointly led by Professor Qin Shukui from Jinling Hospital of Nanjing University of Traditional Chinese Medicine and Professor Li Jin of Shanghai Tongji University Affiliated Oriental Hospital, the "Nimotuzumab Combined with Gemcitabine" was conducted in good faith by 25 large research centers across the country.
The registration clinical study (Notable study) of locally advanced or metastatic pancreatic cancer compared with gemcitabine in the treatment of K-Ras wild-type successfully met the pre-specified primary endpoint.
The conference submission, received a notification today that it was accepted and hired by the conference organizing committee, and selected as the oral report of the conference, congratulations! It is expected to solve the dilemma of the current treatment of pancreatic cancer, the "king of cancer"
.
Expert Profile Professor Qin Shukui Chief Physician and Doctoral Supervisor of Cancer Center of Nanjing Jinling Hospital Distinguished Professor of Nanjing University of Traditional Chinese Medicine and Nanjing Medical University Editor-in-Chief of Journal of Clinical Oncology, a national statistical source journal Former Chairman and current Chairman of the Board of Supervisors of Beijing CSCO Foundation, Expert of the Advisory Committee of Hematology and Oncology Drugs of the State Food and Drug Administration, Chairman of the National Health Commission's Capacity Building and Continuing Education Oncology Expert Committee Tumor diagnosis, treatment and research Professor Li Jin Chairman of Asian Federation of Oncology (FACO) Former Chairman of Chinese Society of Clinical Oncology (CSCO) Chairman of CSCO Foundation Chairman of China Pharmaceutical Promotion Association Oncology Clinical Research Committee Chairman of National Health Commission Capacity Building and Continuation Vice Chairman of Educational Oncology Expert Committee Vice Chairman of Abdominal Tumor Committee of Chinese Medical Continuing Education Association Deputy Editor-in-Chief of Cancer Science Journal Pancreatic cancer is a common clinical malignant tumor that seriously threatens human health and life.
Most patients have reached locally advanced or distant metastases at the time of diagnosis.
The treatment is very difficult, the prognosis is poor, and the survival time is very short.
The treatment has been stagnant for many years
.
Nimotuzumab is the first humanized monoclonal antibody in China developed and produced by Sino-Cuban joint venture Baitai Biopharmaceutical Company
.
In recent years, further clinical studies of nimotuzumab in the treatment of head and neck tumors, cervical cancer, esophageal cancer and pancreatic cancer are in full swing
.
A previous phase II study of nimotuzumab combined with gemcitabine in the treatment of locally advanced or metastatic pancreatic cancer in Germany showed that compared with gemcitabine alone, the nimotuzumab combined with gemcitabine group can significantly prolong the whole population of the combination group.
The overall survival time (OS was 8.
6 months vs 6 months, p=0.
03); for patients with high EGFR expression and K-Ras wild type, the effect was better, and the 1-year OS rate of patients in the combination group and single drug group with high EGFR expression were 36.
4% and 8.
3%, respectively (p=0.
045), while the 1-year OS rates of K-Ras wild-type patients were 53.
5% and 15.
8%, respectively (p=0.
026)
.
The Notable study is a prospective, randomized, controlled, double-blind, national multi-center registration phase III clinical study, which enrolled patients with locally advanced or metastatic pancreatic cancer with wild-type K-Ras gene
.
This is a clinical trial that uses molecular biomarkers to screen enriched populations and uses molecular targeted drugs combined with chemotherapy drugs to achieve precise treatment to achieve excellent results.
Positive results are obtained, which is very valuable and has important clinical value and scientific significance! This will be a breakthrough in the field of pancreatic cancer, which is expected to change the current status of pancreatic cancer treatment and bring the dawn of life to K-Ras wild-type pancreatic cancer patients
.
Therefore, the ASCO Conference Organizing Committee carefully selected the research results from more than 6,300 submissions, and gave an oral report to the world
.
References: 1.
van Erning FN, Mackay TM, van der Geest LGM, et al.
Oncol.
2018 Dec;57(12):1655-1662.
2.
Schultheis B, et al.
Ann Oncol.
2017 Oct 1;28(10 ): 2429-2435.
, Ltd.
, and jointly led by Professor Qin Shukui from Jinling Hospital of Nanjing University of Traditional Chinese Medicine and Professor Li Jin of Shanghai Tongji University Affiliated Oriental Hospital, the "Nimotuzumab Combined with Gemcitabine" was conducted in good faith by 25 large research centers across the country.
The registration clinical study (Notable study) of locally advanced or metastatic pancreatic cancer compared with gemcitabine in the treatment of K-Ras wild-type successfully met the pre-specified primary endpoint.
The conference submission, received a notification today that it was accepted and hired by the conference organizing committee, and selected as the oral report of the conference, congratulations! It is expected to solve the dilemma of the current treatment of pancreatic cancer, the "king of cancer"
.
Expert Profile Professor Qin Shukui Chief Physician and Doctoral Supervisor of Cancer Center of Nanjing Jinling Hospital Distinguished Professor of Nanjing University of Traditional Chinese Medicine and Nanjing Medical University Editor-in-Chief of Journal of Clinical Oncology, a national statistical source journal Former Chairman and current Chairman of the Board of Supervisors of Beijing CSCO Foundation, Expert of the Advisory Committee of Hematology and Oncology Drugs of the State Food and Drug Administration, Chairman of the National Health Commission's Capacity Building and Continuing Education Oncology Expert Committee Tumor diagnosis, treatment and research Professor Li Jin Chairman of Asian Federation of Oncology (FACO) Former Chairman of Chinese Society of Clinical Oncology (CSCO) Chairman of CSCO Foundation Chairman of China Pharmaceutical Promotion Association Oncology Clinical Research Committee Chairman of National Health Commission Capacity Building and Continuation Vice Chairman of Educational Oncology Expert Committee Vice Chairman of Abdominal Tumor Committee of Chinese Medical Continuing Education Association Deputy Editor-in-Chief of Cancer Science Journal Pancreatic cancer is a common clinical malignant tumor that seriously threatens human health and life.
Most patients have reached locally advanced or distant metastases at the time of diagnosis.
The treatment is very difficult, the prognosis is poor, and the survival time is very short.
The treatment has been stagnant for many years
.
Nimotuzumab is the first humanized monoclonal antibody in China developed and produced by Sino-Cuban joint venture Baitai Biopharmaceutical Company
.
In recent years, further clinical studies of nimotuzumab in the treatment of head and neck tumors, cervical cancer, esophageal cancer and pancreatic cancer are in full swing
.
A previous phase II study of nimotuzumab combined with gemcitabine in the treatment of locally advanced or metastatic pancreatic cancer in Germany showed that compared with gemcitabine alone, the nimotuzumab combined with gemcitabine group can significantly prolong the whole population of the combination group.
The overall survival time (OS was 8.
6 months vs 6 months, p=0.
03); for patients with high EGFR expression and K-Ras wild type, the effect was better, and the 1-year OS rate of patients in the combination group and single drug group with high EGFR expression were 36.
4% and 8.
3%, respectively (p=0.
045), while the 1-year OS rates of K-Ras wild-type patients were 53.
5% and 15.
8%, respectively (p=0.
026)
.
The Notable study is a prospective, randomized, controlled, double-blind, national multi-center registration phase III clinical study, which enrolled patients with locally advanced or metastatic pancreatic cancer with wild-type K-Ras gene
.
This is a clinical trial that uses molecular biomarkers to screen enriched populations and uses molecular targeted drugs combined with chemotherapy drugs to achieve precise treatment to achieve excellent results.
Positive results are obtained, which is very valuable and has important clinical value and scientific significance! This will be a breakthrough in the field of pancreatic cancer, which is expected to change the current status of pancreatic cancer treatment and bring the dawn of life to K-Ras wild-type pancreatic cancer patients
.
Therefore, the ASCO Conference Organizing Committee carefully selected the research results from more than 6,300 submissions, and gave an oral report to the world
.
References: 1.
van Erning FN, Mackay TM, van der Geest LGM, et al.
Oncol.
2018 Dec;57(12):1655-1662.
2.
Schultheis B, et al.
Ann Oncol.
2017 Oct 1;28(10 ): 2429-2435.
